Biochemical Reagent
-
BA6333 BI-4020Summary: BI-4020 is a fourth generation, orally active, non-covalent tyrosine kinase inhibitor. -
BA6334 MavelertinibSummary: Mavelertinib is a selective, orally effective and irreversible tyrosine kinase inhibitor with values of 5, 4, 12 and 3 nM for Del, L858R and double mutant T790M/L858R and T790M/Del, respectively.
-
BA6335 PF-06459988Summary: PF-06459988 is an orally active, irreversible and mutant-selective mutant inhibitor.
-
BA6336 ZenocutuzumabSummary: Zenocutuzumab (MCLA-128) is a bispecific humanized antibody.
-
BA6337 RezivertinibSummary: Rezivertinib (BPI-7711) is an orally effective, highly selective and irreversible third-generation tyrosine kinase inhibitor (TKI).
-
BA6338 BI-4142Summary: BI-4142 is a potent and highly selective inhibitor with oral activity.
-
BA6339 SimotinibSummary: Simotinib is a selective, specific, and orally bioavailable tyrosine kinase inhibitor.
-
BA6340 EGFR-IN-3Summary: EGFR-IN-3 is a potent inhibitor.
-
BA6341 NSC689857Summary: NSC689857 is a potent inhibitor.
-
BA6342 EGFR-IN-7Summary: EGFR-IN-7 is a potent and selective kinase inhibitor with oral activity.